Cyclooxygenase-2/prostaglandin E2 pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells

Cancer Letters

Volumn 280, Issue 1, 2009, Pages 93-100

  Lee, Keun Sung ^a   Lee, Hyo Jeong ^a   Ahn, Kwang Seok ^a   Kim, Sun Hee ^a   Nam, Dongwoo ^a   Kim, Dae Keun ^b   Choi, Do Young ^a   Ahn, Kyoo Seok ^a   Lu, Junxuan ^c   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Woosuk University   (South Korea)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Apoptosis; COX 2; Icariside II; PC 3 cells; PGE2

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CYCLOOXYGENASE 2; CYTOCHROME C; EPIMEDIUM KOREANUM EXTRACT; ICARISIDE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLANT EXTRACT; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG INHIBITION; MITOCHONDRIAL MEMBRANE POTENTIAL; NICK END LABELING; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN SECRETION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CYCLOOXYGENASE 2; FLAVONOIDS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; NITRIC OXIDE SYNTHASE TYPE II; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EPIMEDIUM KOREANUM;

EID: 67349233455     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.02.024     Document Type: Article

References (43)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics, 2002. CA-Cancer J. Clin. 55 (2005) 74-108
2. de Reijke T.M., Battermann J.J., van Moorselaar R.J., de Jong I.J., Visser A.P., and Burgers J.S. Practice guideline 'Prostate cancer: diagnosis and treatment'. Ned Tijdschr Geneeskd. 152 (2008) 1771-1775
3. Aggarwal B.B., and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71 (2006) 1397-1421
4. Steller H. Mechanisms and genes of cellular suicide. Science 267 (1995) 1445-1449
5. Kerr J.F. Shrinkage necrosis: a distinct mode of cellular death. J. Pathol. 105 (1971) 13-20
6. Wyllie A.H., Kerr J.F., and Currie A.R. Cell death: the significance of apoptosis. Int. Rev. Cytol. 68 (1980) 251-306
7. Hu W., and Kavanagh J.J. Anticancer therapy targeting the apoptotic pathway. Lancet. Oncol. 4 (2003) 721-729
8. Budihardjo I., Oliver H., Lutter M., Luo X., and Wang X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol. 15 (1999) 269-290
9. Kluck R.M., Bossy-Wetzel E., Green D.R., and Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275 (1997) 1132-1136
10. Liu X., Kim C.N., Yang J., Jemmerson R., and Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 86 (1996) 147-157
11. Gupta S., Srivastava M., Ahmad N., Bostwick D.G., and Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42 (2000) 73-78
12. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., and Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60 (2000) 1306-1311
13. Lee E.O., Lee H.J., Hwang H.S., Ahn K.S., Chae C., Kang K.S., Lu J., and Kim S.H. Potent inhibition of Lewis lung cancer growth by heyneanol A from the roots of Vitis amurensis through apoptotic and anti-angiogenic activities. Carcinogenesis 27 (2006) 2059-2069
14. Zhang D.W., Cheng Y., Wang N.L., Zhang J.C., Yang M.S., and Yao X.S. Effects of total flavonoids and flavonol glycosides from Epimedium koreanum Nakai on the proliferation and differentiation of primary osteoblasts. Phytomedicine 15 (2008) 55-61
15. He W., Sun H., Yang B., Zhang D., and Kabelitz D. Immunoregulatory effects of the herba Epimediia glycoside icariin. Arzneimittelforschung 45 (1995) 910-913
16. Huang X., Zhu D., and Lou Y. A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur. J. Pharmacol. 564 (2007) 26-36
17. Stevens J.F., and Page J.E. Xanthohumol and related prenylflavonoids from hops and beer: to your good health!. Phytochemistry 65 (2004) 1317-1330
18. Park J.S., Park H.Y., Rho H.S., Ahn S., Kim D.H., and Chang I.S. Statistically designed enzymatic hydrolysis for optimized production of icariside II as a novel melanogenesis inhibitor. J. Microbiol. Biotechnol. 18 (2008) 110-117
19. Choi H.J., Eun J.S., Kim D.K., Li R.H., Shin T.Y., Park H., Cho N.P., and Soh Y. Icariside II from Epimedium koreanum inhibits hypoxia-inducible factor-1alpha in human osteosarcoma cells. Eur. J. Pharmacol. 579 (2008) 58-65
20. Minghetti L. Role of COX-2 in inflammatory and degenerative brain diseases. Subcell Biochem. 42 (2007) 127-141
21. Krishnan A.V., Moreno J., Nonn L., Swami S., Peehl D.M., and Feldman D. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J. Bone. Miner. Res. 22 Suppl 2 (2007) V74-V80
22. Patel S., and Chiplunkar S. Role of cyclooxygenase-2 in tumor progression and immune regulation in lung cancer. Indian J. Biochem. Biophys. 44 (2007) 419-428
23. Boulares A.H., Zoltoski A.J., Yakovlev A., Xu M., and Smulson M.E. Roles of DNA fragmentation factor and poly(ADP-ribose) polymerase in an amplification phase of tumor necrosis factor-induced apoptosis. J. Biol. Chem. 276 (2001) 38185-38192
24. Zhang Y., Cichewicz R.H., and Nair M.G. Lipid peroxidation inhibitory compounds from daylily (Hemerocallis fulva) leaves. Life Sci. 75 (2004) 753-763
25. Harper C.E., Patel B.B., Wang J., Eltoum I.A., and Lamartiniere C.A. Epigallocatechin-3-gallate suppresses early stage but not late stage prostate cancer in TRAMP mice: mechanisms of action. Prostate 67 (2007) 1576-1589
26. Guo Y., Wang S., Hoot D.R., and Clinton S.K. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J. Nutr. Biochem. 18 (2007) 408-417
27. Murakami M., and Kudo I. Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr. Pharm. Des. 12 (2006) 943-954
28. Takayama T., Okamura S., Okahisa T., Kaji M., Takeuchi H., and Kimura T. Cancer chemoprevention-basic and clinical aspects. Gan To Kagaku Ryoho 35 (2008) 1067-1071
29. Bacus S.S., Gudkov A.V., Lowe M., Lyass L., Yung Y., Komarov A.P., Keyomarsi K., Yarden Y., and Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene 20 (2001) 147-155
30. Jing Y., Nakaya K., and Han R. Differentiation of promyelocytic leukemia cells HL-60 induced by daidzein in vitro and in vivo. Anticancer. Res. 13 (1993) 1049-1054
31. Pizzolato J.F., and Saltz L.B. The camptothecins. Lancet 361 (2003) 2235-2242
32. Lai G.H., Zhang Z., and Sirica A.E. Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3. Mol. Cancer. Ther. 2 (2003) 265-271
33. Kaufmann S.H., and Hengartner M.O. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 11 (2001) 526-534
34. Reed J.C. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol. Med. 7 (2001) 314-319
35. Haupt Y., Rowan S., Shaulian E., Vousden K.H., and Oren M. Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Genes Dev. 9 (1995) 2170-2183
36. Jiang X., and Wang X. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J. Biol. Chem. 275 (2000) 31199-31203
37. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., and Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 (1997) 479-489
38. Narita M., Shimizu S., Ito T., Chittenden T., Lutz R.J., Matsuda H., and Tsujimoto Y. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl. Acad. Sci. USA. 95 (1998) 14681-14686
39. Oliver F.J., de la Rubia G., Rolli V., Ruiz-Ruiz M.C., de Murcia G., and Murcia J.M. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J. Biol. Chem. 273 (1998) 33533-33539
40. Harris R.E. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem. 42 (2007) 93-126
41. Howe L.R. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 9 (2007) 210
42. Xiao H., and Yang C.S. Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int. J. Cancer. 123 (2008) 983-990
43. Jana N.R. NSAIDs and apoptosis. Cell Mol. Life Sci. 65 (2008) 1295-1301